He is a loan shark, but one that serves a very important function. He, like the rest of us, is taking a calculated risk. And he will be compensated accordingly.

I do believe that he has a good understanding of this company, and what he is risking his money on. It would be poor business to not know.

He engages in high risk lending. Cytodyn,until it has an approval is a high risk venture.

That's what makes this moment so monumental. The only thing holding the share price down is the risk. Revenue changes the risk profile dramatically, and will cause the stock to rise, dilution to end, and our days of borrowing with him will end as well.

To quote Marshawn Lynch "I'm all about that data boss."